domingo, 14 de agosto de 2011

NCI Cancer Bulletin for August 9, 2011 - National Cancer Institute

CCR's Gonzalez and Colleagues Honored for Diagnostic Test
Dr. Frank Gonzalez, Mojdeh Bahar, and Dr. Betty Tong

Dr. Frank Gonzalez, chief of the Laboratory of Metabolism in NCI's Center for Cancer Research (CCR), and Dr. Pedro Fernandez-Salguero, a former CCR fellow who is now a professor in Spain, received the 2011 Federal Laboratory Consortium Award for Excellence in Technology Transfer for developing and transferring a life-saving diagnostic test to the marketplace. The award recognizes those who have done an outstanding job in transferring technology developed in a federal laboratory to partners in the private sector.

Drs. Gonzalez and Fernandez-Salguero determined the molecular basis of 5-fluorouracil (5-FU)-linked toxicity. They discovered a splicing mutation in the gene that encodes dihydropyrimidine dehydrogenase (DPD), an enzyme that is normally involved in degradation of the drug. Patients' sensitivity to 5-FU is directly associated with the presence of a mutated DPD gene and low DPD enzyme activity levels, resulting in the accumulation of 5-FU in the body.

As a result of this work, patients can now be screened for the mutation before 5-FU is administered, which reduces the risk of life-threatening toxicity. The test has been nonexclusively licensed to several companies in Europe and the United States.

Mojdeh Bahar and Dr. Betty Tong of NIH's Office of Technology Transfer [NIH Office of Technology Transfer (OTT)]were recognized for their contribution to the successful transfer of this diagnostic technology to a number of licensees.

In the United States, approximately 275,000 cancer patients receive 5-FU annually. The transfer of this technology through nonexclusive licenses has allowed this diagnostic test to be widely disseminated.

"As a result of these multiple licenses," noted Dr. Gonzalez, "many patients around the world can avoid being treated with a drug that may prove to do them more harm than good."

NCI Cancer Bulletin for August 9, 2011 - National Cancer Institute

NIH Office of Technology Transfer (OTT)>>
NIH Office of Technology Transfer (OTT)

No hay comentarios: